Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2022
Antengene announces Xpovio approved by the TGA in Australia for the treatment of relapsed and/or refractory multiple myeloma and triple class-refractory multiple myeloma
10 March 2022 - Xpovio is the first of a new class of SINE (selective inhibitor of nuclear export) medicines. ...
Posted by Michael Wonder on 11 Mar 2022
ATAGI update following weekly COVID-19 meeting (9 March 2022)
11 March 2022 - ATAGI have not made any new updates since 2 March 2022. ...
Posted by Michael Wonder on 10 Mar 2022
COVID-19 vaccine weekly safety report (10 March 2022)
10 March 2022 - To 6 March 2022, the TGA has received 460 reports which have been assessed as likely ...
Posted by Michael Wonder on 09 Mar 2022
TGA approves provisional determination for Biocelect for COVID-19 vaccine Nuvaxovid
10 March 2022 - The TGA has granted a second provisional determination to Biocelect (on behalf of Novavax) in relation ...
Posted by Michael Wonder on 07 Mar 2022
TGA approves Sogroya
8 March 2022 - Somapacitan is a long‑acting recombinant human growth hormone derivative. ...
Posted by Michael Wonder on 07 Mar 2022
ATAGI update following weekly COVID-19 meeting (2 March 2022)
7 March 2022 - As of 1 March 2022, over 54 million doses of COVID-19 vaccines have been administered in ...
Posted by Michael Wonder on 06 Mar 2022
Australian COVID nasal spray not on shop shelves amid TGA dispute
4 March 2022 - Melbourne start-up Starpharma is at loggerheads with the medicines regulator over the approvals process for its ...
Posted by Michael Wonder on 03 Mar 2022
Medicines Australia welcomes reform efforts to speed up clinical trials
4 March 2022 - Australian patients will have improved access to clinical trials due to reforms to be introduced by ...
Posted by Michael Wonder on 03 Mar 2022
COVID-19 vaccine weekly safety report (3 March 2022)
3 March 2022 - This is the 52nd issue of the COVID-19 vaccine safety report. ...
Posted by Michael Wonder on 03 Mar 2022
Jemperli approved by the TGA
2 March 2022 - Dostarlimab is an anti-programmed cell death protein 1 immunoglobulin G4 humanised monoclonal antibody, derived from a stable ...
Posted by Michael Wonder on 02 Mar 2022
ATAGI recommends Novavax for use as a COVID-19 booster
2 March 2022 - The Australian Technical Advisory Group on Immunisation has recommended the use of the Novavax vaccine as a ...
Posted by Michael Wonder on 28 Feb 2022
ATAGI update following weekly COVID-19 meeting (23 February 2022)
28 February 2022 - ATAGI recommends Spikevax (Moderna) COVID-19 vaccine can be used for primary vaccination in children aged 6-11 ...
Posted by Michael Wonder on 28 Feb 2022
Prescription medicines: applications under evaluation (February 2022)
25 February 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...
Posted by Michael Wonder on 25 Feb 2022
TGA provisionally approves AstraZeneca's combination therapy (tixagevimab and cilgavimab, Evusheld) - for pre-exposure prevention (prophylaxis) of COVID-19
25 February 2022 - On 24 February 2022, the TGA granted provisional approval to AstraZeneca for its tixagevimab and cilgavimab ...
Posted by Michael Wonder on 24 Feb 2022
COVID-19 vaccine weekly safety report (24 February 2022)
24 February 2022 - To 20 February 2022, the TGA has received 451 reports which have been assessed as likely to ...